Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk

Condition:   To Evaluate the Rate of Digestive and Urinary Toxicity Intervention:   Radiation: prostatic boost in brachytherapy with high dose rate (HDR) Sponsor:   Centre Georges Francois Leclerc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials